LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
YI
111, Inc.
There isn't enough reported data to score YI yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
YI Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Under pressure | |
| Strong |
YI's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
YI PE Valuation
YI has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
YI Forward outlook
There aren't enough analyst estimates for YI to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over YI on earnings quality, reporting a profit while its opponent remains loss making.
YI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.79 | -$0.51 |
| Q1 2026 | -$1.46 | -$0.27 |
| Q4 2025 | -$1.14 | -$0.01 |
| Q3 2025 | -$1.21 | +$3.29 |
| Q2 2025 | -$1.28 | +$4.58 |
| Q1 2025 | -$1.19 | +$5.45 |
| Q4 2024 | -$1.13 | +$5.84 |
| Q3 2024 | -$4.50 | +$0.68 |
YI is still losing money, but far less than before: $1.79 per share over the past year, against $12.49 at its worst in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over YI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over YI on profitability, with a higher operating margin.
YI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $345.2M | -28% |
| Q1 2026 | $354.4M | -33% |
| Q4 2025 | $417.4M | -28% |
| Q3 2025 | $450.3M | -17% |
| Q2 2025 | $481.1M | -6.4% |
| Q1 2025 | $529.6M | 0% |
| Q4 2024 | $577.4M | -6.3% |
| Q3 2024 | $540.4M | -1.8% |
YI's revenue has slid since its 2022 peak: $345M last quarter, down 28% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1% | -1 points |
| Q1 2026 | -0.8% | -0.8 points |
| Q4 2025 | -0.2% | 0 points |
| Q3 2025 | -0.1% | -0.2 points |
| Q2 2025 | 0% | -0.1 points |
| Q1 2025 | 0% | -0.1 points |
| Q4 2024 | -0.2% | +4.8 points |
| Q3 2024 | 0.1% | +2.3 points |
YI's operating margin was −1% last quarter, down 1 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over YI on cash generation, producing positive trailing cash flow while its opponent burns cash.
YI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.7M | +$7.5M |
| Q1 2026 | -$13.8M | -181% |
| Q4 2025 | $3.8M | +$13.4M |
| Q3 2025 | $5.7M | -65% |
| Q2 2025 | -$9.2M | -166% |
| Q1 2025 | $16.9M | +3.8% |
| Q4 2024 | -$9.6M | +$21.5M |
| Q3 2024 | $16.5M | +212% |
YI has burned cash in most quarters: −$6M over the past year, against $15M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over YI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
YI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +28.3K shares |
| 1 year | +1.7% | +145K shares |
| 3 years | +5% | +418K shares |
| 5 years | +6.4% | +533K shares |
| Available history | +7.5% | +615K shares |
YI has 9M diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $2M |
| Q3 2024 | — |
YI hasn't bought back shares in the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
YI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -22.3x | Net Cash |
| Q3 2025 | -14.5x | Net Cash |
| Q2 2025 | -14.1x | Net Cash |
| Q1 2025 | -14.0x | Net Cash |
| Q4 2024 | -8.4x | Net Cash |
YI has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
YI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 13.2 | Oversold |
YI's weekly RSI is 28 (oversold) and its Stochastic is 13 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
YI PE vs Healthcare Sector
YI has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has stronger trend alignment. LLY is above 5 of 5 weekly averages versus YI above 0 of 4.
YI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.07 | 7.2% below |
| 20 week MA | $3.47 | 18% below |
| 50 week MA | $4.79 | 41% below |
| 100 week MA | $5.76 | 51% below |
YI is in a downtrend: it's below all four of its weekly moving averages, and 51% below its 100-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over YI on returns for 2026, with the stronger performance.
YI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $11.6 | $7.35 | -36% |
| 2025 | $7.35 | $3.08 | -58% |
| 2026 YTD | $3.08 | $2.85 | -7.5% |
YI has finished every year since 2024 lower, and it's down 7.5% so far in 2026.